UnitedHealthcare Community Plan

ADHD Products
Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328.** If you have questions, please call **800-310-6826.**

This form may contain multiple pages. Please complete all pages to avoid a delay in our decision. Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		

Is the requested medication: □ New or □ Continuation of Therapy? If continuation, list start date: _______________

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: ________________

Section B - Provider Information

First Name:		Last Name: M.D./D.O.		
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _______________

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives

UnitedHealthcare Community Plan

ADHD Products
Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

ALL REQUESTS

□ Yes □ No	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Attention deficit hyperactivity disorder/attention deficit disorder (ADHD/ADD) □ Binge eating disorder (BED) □ Fatigue associated with medical illness in palliative or end of life care □ Fatigue associated with multiple sclerosis □ Mental fatigue secondary to traumatic brain injury (e.g. post-concussion syndrome) □ Narcolepsy
□ Yes □ No	**Is the patient currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge?**
□ Yes □ No	**Does the patient have a history of failure, contraindication, or intolerance to any preferred alternatives for the given diagnosis?** *(If yes, complete Section D above)*

MULTI-SOURCE BRAND MEDICATION REQUESTS

□ Yes □ No	**Does the patient meet any of the following circumstances?** *(If yes, check which applies)* □ The multi-source brand is being requested because of an adverse reaction, allergy or sensitivity to a generic equivalent □ The multi-source brand is being requested due to a therapeutic failure with the generic equivalent □ The multi-source brand is being requested because transition to a generic equivalent could result in destabilization of the patient □ Special clinical circumstances exist that preclude the use of a generic version of the multi-source brand medication for the patient

ATTENTION DEFICIT HYPERACTIVITY DISORDER/ATTENTION DEFICIT DISORDER - KAPVAY / CLONIDINE ER

□ Yes □ No	**Does the patient have a history of failure, contraindication, or intolerance to any of the following?** *(If yes, check which applies and complete Section D above)* □ Guanfacine ER (generic Intuniv) □ Atomoxetine (generic Strattera)

LESS THAN THE FDA APPROVED MINIMUM AGE

□ Yes □ No	**Is the patient unresponsive to, or has had an inadequate response to behavioral therapy?** *(If yes, complete Section D above)*
□ Yes □ No	**Is the patient experiencing moderate-severe continuing disturbance in function despite behavioral therapy?**

Provider Signature: ____ **Date:** ____________________

Confidentiality Notice: This transmission contains confidential information belonging to the sender and United HealthCare. This information is intended only for the use of United HealthCare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.